Reich, K., E. L. Simpson, R. Langley, R. B. Warren, A. Costanzo, H. Saeki, P. Almgren, L. Gjerum, A. Carlsson, M. Gooderham, A. Pinter, M. de Bruin-Weller, and A. Blauvelt. “Tralokinumab Demonstrated a Consistent Safety Profile With up to 42 Months of Treatment in Moderate-to-Severe Atopic Dermatitis: Including Adverse Events of Special Interest”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 6, Nov. 2022, p. s79, doi:10.25251/skin.6.supp.79.